MLYS NASDAQ
Mineralys Therapeutics, Inc.
1W: +1.9%
1M: +3.3%
3M: -1.1%
YTD: -23.8%
1Y: +90.8%
3Y: +83.4%
$26.95
-0.26 (-0.96%)
Weekly Expected Move ±5.4%
$24
$25
$27
$28
$30
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider+$8.8M
Congress—
ETF Holdings—
Key Statistics
Market Cap$2.4B
52W Range12.59-47.65
Volume546,652
Avg Volume1,497,303
Beta0.65
Dividend—
Analyst Ratings
Company Info
CEOJon Congleton
Employees76
SectorHealthcare
IndustryBiotechnology
IPO Date2023-02-10
Websitemineralystx.com
150 N. Radnor Chester Rd.
Radnor, PA 19087
US
Radnor, PA 19087
US
888-378-6240
About Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
Latest News
A Mineralys Insider Banked a $557,000 Options Gain Before a December FDA Date
What to Know About This Mineralys Insider Sale Before a December FDA Date
What a $350,000 Insider Sale Might Mean for Mineralys Ahead of December FDA Decision
Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)
Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Warren Eric | M-Exempt | 7,438 | $13.24 | 2026-07-21 |
| Warren Eric | S-Sale | 7,438 | $26.87 | 2026-07-21 |
| Warren Eric | M-Exempt | 7,438 | $13.24 | 2026-07-21 |
| Rodman David Malcom | M-Exempt | 416 | $15.44 | 2026-07-17 |
| Rodman David Malcom | S-Sale | 416 | $26.53 | 2026-07-17 |